Study identifier:D5180C00016
ClinicalTrials.gov identifier:NCT06023589
EudraCT identifier:N/A
CTIS identifier:2022-502984-39-00
A Multicentre, Randomised, Double-Blind, Parallel-Group Placebo-Controlled, Phase 3, Efficacy and Safety Study of Tezepelumab in 5 to < 12 Year Old Children with Severe Uncontrolled Asthma (HORIZON)
asthma
Phase 3
No
-
All
372
Interventional
5 Years - 11 Years
Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Dec 2024 by AstraZeneca
AstraZeneca
Amgen
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Tezepelumab Participants will be receiving tezepelumab subcutaneous injection | Biological/Vaccine: Tezepelumab Participants will be receiving subcutaneous injection of tezepelumab Other Name: MEDI9929 and AMG157 |
Placebo Comparator: Placebo Participants will be receiving placebo through a subcutaneous injection | Other: Placebo Participants will be receiving subcutaneous injection of matching placebo |